Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 51

1.

Population Pharmacokinetic Analysis and Model-Based Simulations of Aripiprazole for a 1-Day Initiation Regimen for the Long-Acting Antipsychotic Aripiprazole Lauroxil.

Hard ML, Wehr AY, Sadler BM, Mills RJ, von Moltke L.

Eur J Drug Metab Pharmacokinet. 2018 Aug;43(4):461-469. doi: 10.1007/s13318-018-0488-4.

2.

Oliceridine (TRV130), a Novel G Protein-Biased Ligand at the μ-Opioid Receptor, Demonstrates a Predictable Relationship Between Plasma Concentrations and Pain Relief. I: Development of a Pharmacokinetic/Pharmacodynamic Model.

Fossler MJ, Sadler BM, Farrell C, Burt DA, Pitsiu M, Skobieranda F, Soergel DG.

J Clin Pharmacol. 2018 Jun;58(6):750-761. doi: 10.1002/jcph.1076. Epub 2018 Feb 7.

PMID:
29412458
3.
4.

Crowdsourced Asparagus Urinary Odor Population Kinetics.

Ramamoorthy A, Sadler BM, van Hasselt JGC, Elassaiss-Schaap J, Kasichayanula S, Edwards AY, van der Graaf PH, Zhang L, Wagner JA.

CPT Pharmacometrics Syst Pharmacol. 2018 Jan;7(1):34-41. doi: 10.1002/psp4.12264. Epub 2017 Dec 14.

5.

Pharmacokinetic Profile of a 2-Month Dose Regimen of Aripiprazole Lauroxil: A Phase I Study and a Population Pharmacokinetic Model.

Hard ML, Mills RJ, Sadler BM, Wehr AY, Weiden PJ, von Moltke L.

CNS Drugs. 2017 Jul;31(7):617-624. doi: 10.1007/s40263-017-0447-7.

6.

Aripiprazole Lauroxil: Pharmacokinetic Profile of This Long-Acting Injectable Antipsychotic in Persons With Schizophrenia.

Hard ML, Mills RJ, Sadler BM, Turncliff RZ, Citrome L.

J Clin Psychopharmacol. 2017 Jun;37(3):289-295. doi: 10.1097/JCP.0000000000000691.

7.

Omnidirectional beacon-localization using a catadioptric system.

Shen TC, Drost RJ, Sadler BM, Rzasa JR, Davis CC.

Opt Express. 2016 Apr 4;24(7):6931-44. doi: 10.1364/OE.24.006931.

PMID:
27136988
8.

Model-Based Phase 3 Dose Selection for HIV-1 Attachment Inhibitor Prodrug BMS-663068 in HIV-1-Infected Patients: Population Pharmacokinetics/Pharmacodynamics of the Active Moiety, BMS-626529.

Landry I, Zhu L, Abu Tarif M, Hruska M, Sadler BM, Pitsiu M, Joshi S, Hanna GJ, Lataillade M, Boulton DW, Bertz RJ.

Antimicrob Agents Chemother. 2016 Apr 22;60(5):2782-9. doi: 10.1128/AAC.02503-15. Print 2016 May.

9.

Compressive spectral polarization imaging by a pixelized polarizer and colored patterned detector.

Fu C, Arguello H, Sadler BM, Arce GR.

J Opt Soc Am A Opt Image Sci Vis. 2015 Nov 1;32(11):2178-88. doi: 10.1364/JOSAA.32.002178.

PMID:
26560932
10.

Dead time effects in non-line-of-sight ultraviolet communications.

Drost RJ, Sadler BM, Chen G.

Opt Express. 2015 Jun 15;23(12):15748-61. doi: 10.1364/OE.23.015748.

PMID:
26193553
11.

Population pharmacokinetics of dolutegravir in HIV-infected treatment-naive patients.

Zhang J, Hayes S, Sadler BM, Minto I, Brandt J, Piscitelli S, Min S, Song IH.

Br J Clin Pharmacol. 2015 Sep;80(3):502-14. doi: 10.1111/bcp.12639. Epub 2015 Jul 14.

12.

Biased agonism of the μ-opioid receptor by TRV130 increases analgesia and reduces on-target adverse effects versus morphine: A randomized, double-blind, placebo-controlled, crossover study in healthy volunteers.

Soergel DG, Subach RA, Burnham N, Lark MW, James IE, Sadler BM, Skobieranda F, Violin JD, Webster LR.

Pain. 2014 Sep;155(9):1829-35. doi: 10.1016/j.pain.2014.06.011. Epub 2014 Jun 19.

PMID:
24954166
13.

Design of dual-link (wide- and narrow-beam) LED communication systems.

Shen TC, Drost RJ, Davis CC, Sadler BM.

Opt Express. 2014 May 5;22(9):11107-18. doi: 10.1364/OE.22.011107.

PMID:
24921809
14.

Towards a Standard Mixed-Signal Parallel Processing Architecture for Miniature and Microrobotics.

Sadler BM, Hoyos S.

J Res Natl Inst Stand Technol. 2014 Sep 8;119:529-39. doi: 10.6028/jres.119.020. eCollection 2014.

15.

Ultraviolet scattering propagation modeling: analysis of path loss versus range.

Drost RJ, Moore TJ, Sadler BM.

J Opt Soc Am A Opt Image Sci Vis. 2013 Nov 1;30(11):2259-65. doi: 10.1364/JOSAA.30.002259.

PMID:
24322923
16.

An approximate closed-form link loss model for non-line-of-sight ultraviolet communication in noncoplanar geometry.

Wang L, Xu Z, Sadler BM.

Opt Lett. 2011 Apr 1;36(7):1224-6. doi: 10.1364/OL.36.001224.

PMID:
21479037
17.

UV communications channel modeling incorporating multiple scattering interactions.

Drost RJ, Moore TJ, Sadler BM.

J Opt Soc Am A Opt Image Sci Vis. 2011 Apr 1;28(4):686-95. doi: 10.1364/JOSAA.28.000686.

PMID:
21478967
18.

Experimental demonstration of ultraviolet pulse broadening in short-range non-line-of-sight communication channels.

Chen G, Xu Z, Sadler BM.

Opt Express. 2010 May 10;18(10):10500-9. doi: 10.1364/OE.18.010500.

PMID:
20588903
19.

Performance of short-range non-line-of-sight LED-based ultraviolet communication receivers.

He Q, Xu Z, Sadler BM.

Opt Express. 2010 Jun 7;18(12):12226-38. doi: 10.1364/OE.18.012226.

PMID:
20588347
20.

Non-line-of-sight ultraviolet link loss in noncoplanar geometry.

Wang L, Xu Z, Sadler BM.

Opt Lett. 2010 Apr 15;35(8):1263-5. doi: 10.1364/OL.35.001263.

PMID:
20410987
21.

Experimental evaluation of LED-based solar blind NLOS communication links.

Chen G, Abou-Galala F, Xu Z, Sadler BM.

Opt Express. 2008 Sep 15;16(19):15059-68.

PMID:
18795043
22.

Analytical performance study of solar blind non-line-of-sight ultraviolet short-range communication links.

Xu Z, Ding H, Sadler BM, Chen G.

Opt Lett. 2008 Aug 15;33(16):1860-2.

PMID:
18709113
23.

The absolute oral bioavailability and population-based pharmacokinetic modelling of a novel dipeptidylpeptidase-IV inhibitor, vildagliptin, in healthy volunteers.

He YL, Sadler BM, Sabo R, Balez S, Wang Y, Campestrini J, Laurent A, Ligueros-Saylan M, Howard D.

Clin Pharmacokinet. 2007;46(9):787-802.

PMID:
17713976
24.

Pharmacokinetic modeling and simulations of interaction of amprenavir and ritonavir.

Sale M, Sadler BM, Stein DS.

Antimicrob Agents Chemother. 2002 Mar;46(3):746-54.

25.

Clinical pharmacology and pharmacokinetics of amprenavir.

Sadler BM, Stein DS.

Ann Pharmacother. 2002 Jan;36(1):102-18. Review.

PMID:
11816239
26.

Pharmacokinetic study of human immunodeficiency virus protease inhibitors used in combination with amprenavir.

Sadler BM, Gillotin C, Lou Y, Eron JJ, Lang W, Haubrich R, Stein DS.

Antimicrob Agents Chemother. 2001 Dec;45(12):3663-8.

27.

Pharmacokinetics and safety of amprenavir and ritonavir following multiple-dose, co-administration to healthy volunteers.

Sadler BM, Piliero PJ, Preston SL, Lloyd PP, Lou Y, Stein DS.

AIDS. 2001 May 25;15(8):1009-18.

PMID:
11399983
28.

Metabolic disposition and pharmacokinetics of [14C]-amprenavir, a human immunodeficiency virus type 1 (HIV-1) protease inhibitor, administered as a single oral dose to healthy male subjects.

Sadler BM, Chittick GE, Polk RE, Slain D, Kerkering TM, Studenberg SD, Lou Y, Moore KH, Woolley JL, Stein DS.

J Clin Pharmacol. 2001 Apr;41(4):386-96.

PMID:
11304895
29.
30.

Pharmacokinetic Interaction between amprenavir and rifabutin or rifampin in healthy males.

Polk RE, Brophy DF, Israel DS, Patron R, Sadler BM, Chittick GE, Symonds WT, Lou Y, Kristoff D, Stein DS.

Antimicrob Agents Chemother. 2001 Feb;45(2):502-8.

31.
32.

Pharmacokinetic interaction between amprenavir and clarithromycin in healthy male volunteers.

Brophy DF, Israel DS, Pastor A, Gillotin C, Chittick GE, Symonds WT, Lou Y, Sadler BM, Polk RE.

Antimicrob Agents Chemother. 2000 Apr;44(4):978-84.

33.

Single-dose pharmacokinetics of amprenavir, a human immunodeficiency virus type 1 protease inhibitor, in subjects with normal or impaired hepatic function.

Veronese L, Rautaureau J, Sadler BM, Gillotin C, Petite JP, Pillegand B, Delvaux M, Masliah C, Fosse S, Lou Y, Stein DS.

Antimicrob Agents Chemother. 2000 Apr;44(4):821-6.

34.

Pharmacokinetic interaction between ketoconazole and amprenavir after single doses in healthy men.

Polk RE, Crouch MA, Israel DS, Pastor A, Sadler BM, Chittick GE, Symonds WT, Gouldin W, Lou Y.

Pharmacotherapy. 1999 Dec;19(12):1378-84.

PMID:
10600086
35.
36.

Efficacy and pharmacokinetics of atovaquone and proguanil in children with multidrug-resistant Plasmodium falciparum malaria.

Sabchareon A, Attanath P, Phanuaksook P, Chanthavanich P, Poonpanich Y, Mookmanee D, Chongsuphajaisiddhi T, Sadler BM, Hussein Z, Canfield CJ, Hutchinson DB.

Trans R Soc Trop Med Hyg. 1998 Mar-Apr;92(2):201-6.

PMID:
9764334
37.

In vitro antiviral activity of 141W94 (VX-478) in combination with other antiretroviral agents.

St Clair MH, Millard J, Rooney J, Tisdale M, Parry N, Sadler BM, Blum MR, Painter G.

Antiviral Res. 1996 Jan;29(1):53-6.

PMID:
8721545
38.

Acousto-optic cyclostationary signal processing.

Sadler BM.

Appl Opt. 1995 Aug 10;34(23):5091-9. doi: 10.1364/AO.34.005091.

PMID:
21052354
39.

Prolonged, but not diminished, zidovudine absorption induced by a high-fat breakfast.

Shelton MJ, Portmore A, Blum MR, Sadler BM, Reichman RC, Morse GD.

Pharmacotherapy. 1994 Nov-Dec;14(6):671-7.

PMID:
7885970
40.

Pharmacokinetics of methamphetamine self-administered to human subjects by smoking S-(+)-methamphetamine hydrochloride.

Cook CE, Jeffcoat AR, Hill JM, Pugh DE, Patetta PK, Sadler BM, White WR, Perez-Reyes M.

Drug Metab Dispos. 1993 Jul-Aug;21(4):717-23.

PMID:
8104133
41.

Pharmacokinetics of oral methamphetamine and effects of repeated daily dosing in humans.

Cook CE, Jeffcoat AR, Sadler BM, Hill JM, Voyksner RD, Pugh DE, White WR, Perez-Reyes M.

Drug Metab Dispos. 1992 Nov-Dec;20(6):856-62.

PMID:
1362938
45.

Drug level monitoring in a double-blind multicenter trial: false-positive zidovudine measurements in AIDS clinical trials group protocol 019.

Krogstad DJ, Eveland MR, Lim LL, Volberding PA, Sadler BM.

Antimicrob Agents Chemother. 1991 Jun;35(6):1160-4.

46.

Plasma levels of methamphetamine after smoking of methamphetamine hydrochloride.

Cook CE, Jeffcoat AR, Perez-Reyes M, Sadler BM, Hill JM, White WR, McDonald S.

NIDA Res Monogr. 1990;105:578-9. No abstract available.

PMID:
1876127
47.

Developmental toxicity of 1,1,1-trichloroethane in CD rats.

George JD, Price CJ, Marr MC, Sadler BM, Schwetz BA, Birnbaum LS, Morrissey RE.

Fundam Appl Toxicol. 1989 Nov;13(4):641-51.

PMID:
2620788
48.

Cocaine disposition in humans after intravenous injection, nasal insufflation (snorting), or smoking.

Jeffcoat AR, Perez-Reyes M, Hill JM, Sadler BM, Cook CE.

Drug Metab Dispos. 1989 Mar-Apr;17(2):153-9.

PMID:
2565204
49.

Effect of model trauma on the turnover of protein and hemoprotein components of hepatic microsomal membrane in immature rats.

George JD, Sadler BM, Rosen GM, Rauckman EJ.

Dev Pharmacol Ther. 1985;8(4):243-53.

PMID:
3839742
50.

Metabolism, disposition and excretion of [14C]melamine in male Fischer 344 rats.

Mast RW, Jeffcoat AR, Sadler BM, Kraska RC, Friedman MA.

Food Chem Toxicol. 1983 Dec;21(6):807-10.

PMID:
6686586

Supplemental Content

Loading ...
Support Center